A small molecule STING activator that is available orally, MSA-2, has been demonstrated to be an effective activator that can induce tumor regression in mice and produce sustained antitumor immunity alongside activation of IFN-β secretion in a variety of syngeneic murine tumor models. This evidence concerns the gene IFNB1 and neoplasm.